Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 neoadjuvant trastuzumab deruxtecan for HER2-positive gastric or gastroesophageal junction adenocarcinoma
jRCT2031210313Phase 2Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab deruxtecan in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Major pathological response rate. Started Sep 2021; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2031210313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210313.